Investment bank Bernstein has downgraded Nuvalent's stock rating to 'underperform' due to concerns over the pharmaceutical company's planned acquisition by GlaxoSmithKline (GSK). The company's shares have been under pressure since the acquisition deal was announced last year, and Bernstein's downgrading of its stock rating is likely to exacerbate this trend. The GSK acquisition deal, worth around £3.6 billion, would see Nuvalent become a subsidiary of the British pharmaceutical giant.
According to a report by Bernstein, the acquisition deal faces significant regulatory hurdles, which could impact Nuvalent's ability to deliver on its growth potential. The investment bank has also expressed concerns over the potential impact of the deal on Nuvalent's research and development capabilities. As a result, Bernstein has downgraded Nuvalent's stock rating from 'market perform' to 'underperform', citing a 30% potential decline in the company's share price over the next 12 months.
The downgrading of Nuvalent's stock rating by Bernstein is likely to have a ripple effect on the UK stock market, with the FTSE 100 index potentially feeling the impact. The GSK acquisition deal is one of several significant transactions in the pharmaceutical sector, and investors are closely watching the developments in this space. The news is also likely to be of interest to UK investors and shareholders who hold Nuvalent shares, as well as those who are considering investing in the pharmaceutical sector.
Nuvalent's shares have already fallen by around 20% since the acquisition deal was announced, and Bernstein's downgrading of its stock rating is likely to exacerbate this trend. The company's market value has fallen to around £2.7 billion, down from £3.4 billion at the time of the acquisition announcement.
The Bank of England has been keeping a close eye on the UK stock market, and a potential decline in Nuvalent's share price could have implications for the broader market. The central bank has been raising interest rates to combat inflation, and a decline in the stock market could impact consumer confidence and spending.